WO2004039324A3 - Anti-hiv (sl9) compounds - Google Patents

Anti-hiv (sl9) compounds Download PDF

Info

Publication number
WO2004039324A3
WO2004039324A3 PCT/US2003/033977 US0333977W WO2004039324A3 WO 2004039324 A3 WO2004039324 A3 WO 2004039324A3 US 0333977 W US0333977 W US 0333977W WO 2004039324 A3 WO2004039324 A3 WO 2004039324A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
hiv
response
epitopes
polynucleotides
Prior art date
Application number
PCT/US2003/033977
Other languages
French (fr)
Other versions
WO2004039324A2 (en
Inventor
Charles A Nicolette
Bruce D Walker
Original Assignee
Genzyme Corp
Massachusetts Gen Hospital
Charles A Nicolette
Bruce D Walker
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp, Massachusetts Gen Hospital, Charles A Nicolette, Bruce D Walker filed Critical Genzyme Corp
Priority to AU2003284162A priority Critical patent/AU2003284162A1/en
Publication of WO2004039324A2 publication Critical patent/WO2004039324A2/en
Publication of WO2004039324A3 publication Critical patent/WO2004039324A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Abstract

The present invention provides synthetic compounds, antibodies that recognize and bind to these compounds, polynucleotides that encode these compounds, and immune effector cells raised in response to presentation of these epitopes. The invention further provides methods for inducing an immune response and administering immunotherapy to a subject by delivering the compositions of the invention.
PCT/US2003/033977 2002-10-28 2003-10-24 Anti-hiv (sl9) compounds WO2004039324A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003284162A AU2003284162A1 (en) 2002-10-28 2003-10-24 Anti-hiv (sl9) compounds

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42203802P 2002-10-28 2002-10-28
US60/422,038 2002-10-28

Publications (2)

Publication Number Publication Date
WO2004039324A2 WO2004039324A2 (en) 2004-05-13
WO2004039324A3 true WO2004039324A3 (en) 2004-12-29

Family

ID=32230313

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/033977 WO2004039324A2 (en) 2002-10-28 2003-10-24 Anti-hiv (sl9) compounds

Country Status (2)

Country Link
AU (1) AU2003284162A1 (en)
WO (1) WO2004039324A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6248564B1 (en) * 1997-08-29 2001-06-19 Harvard University Mutant MHC class I molecules
US20020172683A1 (en) * 2001-02-27 2002-11-21 Olivier Schwartz MHC-I-restricted presentation of HIV-1 virion antigens without viral replication. Application to the stimulation of CTL and vaccination in vivo; analysis of vaccinating composition in vitro

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6248564B1 (en) * 1997-08-29 2001-06-19 Harvard University Mutant MHC class I molecules
US20020172683A1 (en) * 2001-02-27 2002-11-21 Olivier Schwartz MHC-I-restricted presentation of HIV-1 virion antigens without viral replication. Application to the stimulation of CTL and vaccination in vivo; analysis of vaccinating composition in vitro

Also Published As

Publication number Publication date
WO2004039324A2 (en) 2004-05-13
AU2003284162A1 (en) 2004-05-25
AU2003284162A8 (en) 2004-05-25

Similar Documents

Publication Publication Date Title
WO2004091543A3 (en) Method of treating autoimmune disease by inducing antigen presentation by tolerance inducing antigen presenting cells
WO2004022709A3 (en) Epitope sequences
EP2298805A3 (en) Optimized Fc variants and methods for their generation
WO2006073748A3 (en) Antibodies against antigen presenting cells and uses thereof
WO2004099249A3 (en) Optimized fc variants and methods for their generation
EP2270045B8 (en) Antibodies against Clostridium difficile toxins and uses thereof
HK1050695A1 (en) Methods for generating human monoclonal antibodies
WO2008033966A3 (en) Alphavirus replicon particles matched to protein antigens as immunological adjuvants
WO2005037190A3 (en) Multiplex vaccines
EP2292636A3 (en) Process for concentration of antibodies and therapeutic products thereof
WO2006036745A3 (en) Il-23p40 specific immunoglobulin derived proteins, compositions, epitopes, methods and uses
WO2006121810A3 (en) Trimeric ox40-immunoglobulin fusion protein and methods of use
WO2002064057A3 (en) Use of cell penetrating peptides to generate antitumor immunity
WO2004033663A3 (en) Carbohydrate-based synthetic vaccines for hiv
WO2009114040A3 (en) Anti-il-12/23p40 antibodies, epitopes, formulations, compositions, methods and uses
WO2001092306A3 (en) Therapeutic compounds for ovarian cancer
WO2005023302A3 (en) Anti-cd20 therapy of ocular disorders
WO2005086947A3 (en) Method for inhibiting immune complex formation in a subjetc
AU2002354806A1 (en) Parathyroid hormone antibodies and related methods
WO2001070766A3 (en) Therapeutic anti-cytomegalovirus compounds
WO2001068677A3 (en) Derivatives of breast canacer antigen her-2 for therapeutical use
WO2004039324A3 (en) Anti-hiv (sl9) compounds
WO2003037264A3 (en) Therapeutic anti-hiv (vpr) compounds
WO2003091395A3 (en) Inhibition of immune complex formation
WO2003091383A3 (en) Epha2 antigen t epitopes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP